Doctors plan to prescribe bevacizumab (Avastin) despite legal threats from drug companies, and against GMC and NICE guidance. But is the GMC’s and the MHRA’s advice to doctors correct? Deborah investigated the latest in the debate around off-label use of bevacizumab¬†https://www.bmj.com/content/359/bmj.j5016

Write A Comment